Laminin subunit beta 3 (LAMB3) has emerged as a critical player in the molecular landscape of cancer, yet its precise role in gastric cancer (GC) progression has remained elusive until now. A groundbreaking study published in the British Journal of Cancer unravels the intricate mechanisms by which LAMB3 exacerbates malignancy in GC, shedding light on a novel molecular axis that could revolutionize therapeutic approaches. This research uncovers how LAMB3 orchestrates the sustained activation of the PI3K-Akt pathway—one of the most prominent signaling routes involved in tumor growth and survival—through targeted degradation of PHLPP2 mRNA mediated by the RNA-binding protein SAMD4A.

Gastric cancer continues to rank among the leading causes of cancer mortality worldwide, with its complex molecular underpinnings posing a significant challenge to effective treatment. Despite advances in understanding various oncogenic drivers, the involvement of extracellular matrix components like LAMB3 has been underappreciated. Laminins, as glycoproteins critical for basement membrane structure and signaling, influence cell adhesion, migration, and differentiation. The aberrant overexpression of LAMB3 in various cancers hinted at its potential role in tumor aggressiveness, yet the mechanistic details remained uncharted until the present study’s in-depth molecular analyses.

The authors employed a comprehensive experimental framework combining transcriptomic analysis, RNA immunoprecipitation, and functional assays in gastric cancer cell lines and murine xenograft models. They demonstrated that LAMB3 upregulation correlates with increased GC cell proliferation, invasion, and metastatic potential. More strikingly, LAMB3 was found to exert these oncogenic effects by destabilizing PHLPP2 mRNA, a known tumor suppressor that negatively regulates the PI3K-Akt signaling axis. This discovery positions LAMB3 as a pivotal regulator of intracellular signaling networks that propel oncogenesis.

At the heart of this regulatory pathway lies SAMD4A, an RNA-binding protein previously unlinked to gastric cancer pathophysiology. The study reveals that LAMB3 enhances the interaction between SAMD4A and PHLPP2 mRNA, promoting its degradation through post-transcriptional mechanisms. This SAMD4A-mediated mRNA decay leads to a marked reduction in PHLPP2 protein levels, unleashing hyperactivation of the PI3K-Akt pathway. Such persistent signaling drives uncontrolled cellular proliferation and survival, hallmark features of aggressive cancer phenotypes.

Mechanistically, the suppression of PHLPP2 removes a vital check on Akt phosphorylation, facilitating an unchecked flow of pro-survival signals inside the cancer cells. The PI3K-Akt pathway modulates diverse cellular functions, including metabolism, apoptosis resistance, and cell cycle progression. By unraveling this axis, the study prominently positions LAMB3—and its downstream effectors—as promising biomarkers and therapeutic targets in GC, where tailored interventions are urgently needed.

Notably, the research team extended their findings to patient-derived GC tissues, confirming that elevated LAMB3 expression significantly correlates with poor prognosis and advanced disease stages. The clinical relevance strengthens the translational potential of targeting the LAMB3-SAMD4A-PHLPP2 axis, suggesting that disrupting this molecular cascade might curtail tumor progression and improve patient outcomes.

Beyond the intrinsic mechanistic insights, the study raises intriguing possibilities for drug development. Small molecules or RNA-based therapeutics that inhibit LAMB3 expression or interfere with SAMD4A’s binding to PHLPP2 mRNA could restore tumor suppressor function and dampen aberrant signaling. Given the centrality of PI3K-Akt in many cancers, such interventions might have broad applicability beyond just gastric malignancies, positioning this discovery at the forefront of precision oncology.

Moreover, the findings provoke a reevaluation of how extracellular matrix components, traditionally viewed as structural elements, actively participate in intracellular oncogenic signaling. The delineation of LAMB3’s role in manipulating RNA stability via SAMD4A opens a relatively unexplored frontier in cancer biology: the crosstalk between the extracellular milieu and post-transcriptional gene regulation. This interplay hints at a complex regulatory network that underpins cancer cells’ adaptability and survival in hostile microenvironments.

The study also highlights the importance of integrating multi-omics data to dissect the sophisticated molecular interactions governing cancer progression. Through the use of advanced RNA immunoprecipitation and sequencing techniques, the researchers mapped the dynamic interactions between RNA-binding proteins and specific mRNA targets, elucidating a critical post-transcriptional regulatory node controlled by LAMB3. Such approaches exemplify the power of cutting-edge molecular biology tools in unveiling hidden layers of cancer biology.

Future research is poised to explore whether similar mechanisms operate in other epithelial cancers where LAMB3 is dysregulated. Comparative analyses across tumor types could validate the universality of this pathway, potentially expanding the clinical impact of these findings. Furthermore, understanding how LAMB3 expression itself is regulated, including potential epigenetic and transcriptional modulators, could unveil additional therapeutic leverage points.

Identifying effective inhibitors of the LAMB3-SAMD4A interaction stands as an exciting therapeutic frontier. While challenging, the small interface between RNA-binding proteins and target mRNAs offers a unique opportunity to develop molecules with high specificity and minimal off-target effects. Collaboration between molecular biologists, chemists, and clinical researchers will be critical to translate these molecular insights into viable therapies.

In summary, this landmark study elucidates a novel molecular mechanism whereby LAMB3 promotes gastric cancer progression through the SAMD4A-mediated degradation of PHLPP2 mRNA, sustaining PI3K-Akt signaling. By connecting extracellular matrix components to post-transcriptional gene regulation and oncogenic signaling, it not only advances fundamental understanding of gastric cancer biology but also charts a promising path toward innovative treatment strategies. As gastric cancer continues to exact a heavy toll worldwide, such pioneering research offers new hope for improved diagnosis, prognosis, and therapeutic intervention.

The implications of this discovery extend beyond the realm of gastric cancer, potentially influencing broader fields of oncology and RNA biology. As the scientific community delves deeper into the non-canonical functions of extracellular proteins and RNA-binding factors, the intricate tapestry of cancer’s molecular underpinnings becomes progressively clearer. The LAMB3-SAMD4A-PHLPP2 axis may well become a focal point in the ongoing quest to outmaneuver cancer at its molecular roots.

With continued investment in translational research and clinical trials inspired by these findings, the next decade could herald significant breakthroughs in managing gastric cancer and related malignancies. This study stands as a testament to the power of multidisciplinary approaches in tackling one of humanity’s most formidable health challenges, combining molecular precision with clinical urgency to pave the way toward a future where gastric cancer progression can be effectively stalled or reversed.

Subject of Research: Molecular mechanisms driving gastric cancer malignancy involving LAMB3-mediated regulation of mRNA stability and signaling pathways.

Article Title: LAMB3 drives gastric cancer progression through SAMD4A-mediated degradation of PHLPP2 mRNA leading to sustained PI3K-Akt activation.

Article References:
Guo, J., Cai, F., Zhang, M. et al. LAMB3 drives gastric cancer progression through SAMD4A-mediated degradation of PHLPP2 mRNA leading to sustained PI3K-Akt activation. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03496-w

Image Credits: AI Generated

DOI: 2026-06-17

In a groundbreaking study published recently, researchers have uncovered a pivotal molecular mechanism driving the aggressive behavior of lung cancer cells. The investigation centers around the microRNA miR-9-5p, a small non-coding RNA molecule intricately regulated by the kinase IKKα. This discovery elucidates how miR-9-5p orchestrates lung tumor growth and invasiveness through the modulation of the CDH1/Wnt/β-catenin signaling pathway, a critical axis in cell adhesion and proliferation. As lung cancer remains the leading cause of cancer-related mortality worldwide, identifying such novel regulatory mechanisms holds immense promise for therapeutic innovation.

The research team, led by Besta, S., Roupakia, E., and Kanaki, Z., meticulously dissected the molecular interplay governing miR-9-5p expression and function within the intricate cancer signaling environment. Their study highlights that IKKα, beyond its established role in the NF-κB pathway, exerts fine-tuned control over this specific microRNA, effectively shaping the oncogenic landscape. Through a series of advanced molecular assays, including chromatin immunoprecipitation and luciferase reporter analyses, the researchers demonstrated that IKKα activity directly influences miR-9-5p transcriptional dynamics, pointing to a novel layer of regulatory complexity.

miR-9-5p has previously been implicated in various malignancies, yet its precise contributions remained ambiguous. This study definitively links miR-9-5p to the suppression of CDH1 (E-cadherin), a hallmark molecule responsible for maintaining epithelial integrity. Loss of E-cadherin function is a well-recognized driver of epithelial-to-mesenchymal transition (EMT), a process by which cancer cells gain migratory and invasive capabilities. By downregulating CDH1 via miR-9-5p, lung cancer cells effectively dismantle their adhesion properties, facilitating dissemination and metastasis.

Integral to this regulatory network is the activation of the canonical Wnt/β-catenin signaling pathway, which the study identifies as a downstream consequence of CDH1 suppression. β-catenin, a multifunctional protein, plays dual roles in cell-cell adhesion complexes and nuclear transcriptional activation. Dysregulation of this pathway is a hallmark of many cancers, contributing not only to uncontrolled proliferation but also to resistance against therapeutic interventions. The newfound connection between miR-9-5p and Wnt/β-catenin signaling unravels a compelling oncogenic circuit poised for targeted intervention.

Using lung cancer cell lines and patient-derived tumor samples, the investigators provided robust evidence that overexpression of miR-9-5p correlates with heightened tumor aggressiveness and poor clinical outcomes. Functional analyses revealed that silencing miR-9-5p reinstituted CDH1 expression, attenuating invasive behaviors and restoring epithelial characteristics. These findings propel miR-9-5p into the spotlight as a master regulator capable of toggling cancer cell phenotype and metastatic potential.

Of notable significance is the implication of IKKα as the upstream modulator of this microRNA. Historically recognized for its pivotal function in inflammatory signaling cascades, IKKα’s emerging role in microRNA regulation bridges inflammation and oncogenesis at a molecular crossroads. This intersection offers exciting prospects for therapeutic targeting, as dual inhibition could suppress both pro-tumorigenic inflammation and invasive cancer phenotypes mediated through miR-9-5p.

The authors leveraged state-of-the-art sequencing technologies to map genome-wide interactions, confirming that IKKα binds specific regulatory elements proximal to the miR-9-5p gene locus. This direct interaction suggests that pharmacological modulation of IKKα kinase activity might effectively recalibrate microRNA expression profiles, thus impairing tumorigenic signaling networks at their root. Such mechanistic insights lay the foundation for developing precision medicines tailored to disrupt this pathogenic axis.

Lung cancer, notorious for its heterogeneity and adaptability, frequently evades conventional therapies through mechanisms such as EMT and Wnt pathway activation. Unraveling the molecular underpinnings of these processes, as achieved by this work, enables the design of novel intervention strategies that could circumvent drug resistance. By targeting miR-9-5p or its regulatory kinase IKKα, future treatments may convert invasive tumors into more differentiated, therapeutically vulnerable states.

Importantly, the study’s exploration of the IKKα-miR-9-5p-CDH1/Wnt axis underscores the interconnectedness of signaling pathways and gene regulatory networks in cancer biology. Such systems-level understanding propels the field beyond isolated gene targets toward integrated models that better predict treatment responses and disease progression. The findings thus represent a paradigm shift in conceptualizing lung cancer’s molecular circuitry.

Beyond its biological implications, this discovery carries significant translational potential. miR-9-5p could serve as a biomarker for aggressive lung cancers, guiding treatment decisions and prognostic assessments. Additionally, small molecule inhibitors or RNA-based therapeutics designed to disrupt IKKα activity or miR-9-5p function may augment existing regimens, potentially enhancing survival rates and quality of life for patients afflicted with this formidable disease.

This study also invites deeper inquiry into whether similar regulatory modules operate in other cancer types, given the conserved roles of IKKα, miR-9-5p, and the Wnt pathway across tissues. Such cross-cancer analyses could reveal universal principles of tumor biology and expand the therapeutic utility of targeting this molecular axis. The research thus sets the stage for broader investigations with wide-reaching clinical impact.

Mechanistically, the intricate balance between miR-9-5p-mediated repression of CDH1 and activation of Wnt/β-catenin signaling exemplifies how microRNAs act as critical nodes in signaling networks. By fine-tuning gene expression post-transcriptionally, microRNAs integrate diverse signals to execute complex cellular programs that dictate tumor behavior. The elucidation of this IKKα-microRNA module enriches our comprehension of non-coding RNA-mediated oncogenic regulation.

Furthermore, the work elucidates how inflammatory kinases such as IKKα intersect with epigenetic and transcriptional machinery to modulate microRNA landscapes. This context expands the conceptual framework of inflammation-driven carcinogenesis, linking kinase signaling, chromatin remodeling, and RNA biology. Therapeutic strategies arising from such multi-dimensional insights promise higher specificity and efficacy.

In summary, this seminal research sheds light on an uncharted regulatory cascade central to lung cancer aggressiveness. By mapping how IKKα drives the expression of the microRNA miR-9-5p, which in turn orchestrates CDH1 repression and Wnt/β-catenin pathway activation, the study unravels a critical oncogenic driver. These insights open new avenues for targeted therapies, potentially revolutionizing treatment paradigms for one of the deadliest human malignancies.

With the rapid advancement of molecular oncology, understanding how kinases, non-coding RNAs, and signaling pathways cooperate to fuel tumor progression is paramount. This research epitomizes the progress toward a more nuanced, mechanism-based approach for combatting lung cancer. As future studies build on these foundational discoveries, hope grows for effective interventions that can halt or reverse malignancy’s deadly march.

Ultimately, the revelation of the IKKα-miR-9-5p-CDH1/Wnt axis heralds a new era of lung cancer biology, emphasizing the power of integrated molecular approaches in uncovering therapeutic targets. The ongoing challenge lies in translating these findings from bench to bedside, a pursuit fueled by the promise of improving patient outcomes and conquering cancer’s complexity.

Subject of Research: The regulatory role of IKKα in modulating the microRNA miR-9-5p and its impact on lung cancer growth and invasiveness via the CDH1/Wnt/β-catenin signaling pathway.

Article Title: The IKKα-regulated microRNA miR-9-5p mediates lung cancer growth and invasiveness via CDH1/Wnt/β-catenin signalling.

Article References: Besta, S., Roupakia, E., Kanaki, Z. et al. The IKKα-regulated microRNA miR-9-5p mediates lung cancer growth and invasiveness via CDH1/Wnt/β-catenin signalling. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03195-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03195-8

As the global population ages, understanding the biological mechanisms linking muscle deterioration and cancer progression has become increasingly imperative. A groundbreaking study led by scientists at Duke-NUS Medical School in Singapore has illuminated a novel cellular communication pathway whereby ageing skeletal muscle influences tumor growth. This pioneering research reveals that sarcopenia, the age-related decline of muscle mass and strength, not only compromises mobility but may actively promote cancer development through alterations in extracellular vesicle secretion.

Extracellular vesicles, tiny membranous particles secreted by virtually every cell type, have emerged as critical conveyors of intercellular communication. These vesicles ferry a diverse cargo of proteins, lipids, and nucleic acids, including microRNAs, modulating the behavior of recipient cells in physiological and pathological contexts. The Duke-NUS team discovered that ageing muscles secrete significantly fewer extracellular vesicles, and those released are compositionally altered, particularly exhibiting a reduction in the microRNA known as miR-7a-5p. This small regulatory RNA is instrumental in suppressing tumorigenic pathways, suggesting that its decline may contribute to an environment conducive to cancer growth.

The study meticulously delineates how the biogenesis and release of muscle-derived extracellular vesicles are governed by the NOTCH-SDC2 signaling axis — a pathway previously recognized for its role in cell differentiation and tissue maintenance. With advancing age, the activity of this pathway diminishes, leading to disrupted formation of vesicles and impaired delivery of tumor-suppressive signals. Intriguingly, the researchers found that physical exercise could reverse this decline, reactivating the NOTCH-SDC2 pathway, restoring vesicle production, and reinstating the protective role of miR-7a-5p-containing extracellular vesicles.

These findings represent a significant advance in our understanding of sarcopenia’s impact beyond musculoskeletal decline, positioning weakened muscle as a contributor to oncogenesis. By establishing a direct molecular link between muscle ageing and tumor progression, the study opens promising avenues for novel therapeutic strategies aimed at harnessing or mimicking muscle-derived extracellular vesicles to inhibit cancer development.

Clinically, the observed correlation between low muscle mass and advanced cancer stages has often been attributed to poor patient fitness; however, this research highlights an active biological mechanism through which muscle health influences tumor biology. Co-investigator Dr. Kenon Chua emphasizes the clinical ramifications, underscoring that muscle-secreted molecules extend their benefits beyond physical function to systemic health. This insight reinforces the critical importance of maintaining muscle volume and quality through regular resistance and aerobic exercise, especially in older adults.

The implications extend to cancer prevention and management, suggesting that interventions aimed at preserving or enhancing muscle function could mitigate oncogenic risks. Furthermore, the specific decline of miR-7a-5p in extracellular vesicles presents an attractive biomarker candidate for assessing cancer susceptibility in individuals suffering from sarcopenia. Detecting such biomarkers could enable earlier identification of at-risk populations, facilitating timely intervention.

Future research directions include validating these mechanisms in human subjects and exploring the translational potential of muscle-derived extracellular vesicles. The ability to pharmacologically stimulate the NOTCH-SDC2 pathway or supplement miR-7a-5p may lead to innovative therapeutics that counteract age-associated cancer risks. Moreover, the study’s insights advocate for integrating physical activity programs into public health policies targeting healthy ageing.

Assistant Professor Tang Hong-Wen, the study’s senior author, remarks on the broader significance of the findings: the muscle-to-tumor communication pathway exemplifies how systemic tissue health influences malignancy, bridging disciplines across oncology, gerontology, and cellular biology. It also emphasizes the hidden complexity of extracellular vesicle-mediated signaling in maintaining tissue homeostasis and restraining disease progression.

This research was conducted under the HEAL (Healthy ageing, Executive function and Ambulatory Longevity) programme, a collaboration that underscores Singapore’s commitment to pioneering science aimed at improving the quality of life in elderly populations. Supported by a consortium of grants from Singapore’s Ministry of Education, the National Medical Research Council, and the National Research Foundation, the study exemplifies a successful synergy between fundamental biology and clinical relevance.

By integrating rigorous experimental methodologies, including high-resolution electron microscopy and molecular profiling, with translational objectives, the Duke-NUS team has unveiled new biological insights with far-reaching implications. The study underscores the crucial role of microRNAs in extracellular vesicle function and highlights the adaptability of their biogenesis pathways to lifestyle factors such as exercise.

In summary, this research reframes our understanding of muscle ageing not simply as a matter of diminished strength and mobility but as a dynamic contributor to systemic disease processes including cancer. The potential for exercise and related interventions to restore vesicle-mediated tumor suppression offers hope for innovative, holistic strategies against cancer that encompass musculoskeletal health as a critical component.

Subject of Research: Cells

Article Title: Sarcopenia promotes tumorigenesis by disrupting NOTCH-SDC2-regulated biogenesis of muscle-derived extracellular vesicles

News Publication Date: 17 June 2026

Web References: https://www.nature.com/articles/s41467-026-72410-y

References: Chen L-K, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment, American Medical Directors Association. 2019;21(3):300-307.e2.

Image Credits: Goh Kah Yong, Duke-NUS Medical School

Keywords: Sarcopenia, Extracellular Vesicles, MicroRNA, miR-7a-5p, NOTCH-SDC2 pathway, Muscle Ageing, Tumorigenesis, Cancer Biology, Exercise, Biomarkers, Cellular Communication, Healthy Ageing